Lincoln International Adds Don Matz as Managing Director, Establishing Pharmaceutical Services M&A Coverage

Lincoln International, a global investment banking advisory firm, is pleased to announce the addition of Don Matz as a Managing Director in its Healthcare Group. Based in the firm’s New York office, Don brings nearly 20 years of experience executing both sell-side and buy-side transactions within healthcare, including extensive focus on pharmaceutical services.

“Don’s hiring comes at a pivotal time for the pharmaceutical services sector,” said Roderick O’Neill, Managing Director, Global Head of Healthcare Investment Banking at Lincoln International. “Private equity interest in pharmaceutical services platforms has flourished in recent years, and our clients will be well-served by his deep experience advising across the pharmaceutical development continuum.”

Over the last five years, biopharma has raised over $400 billion through the public and private funding markets, and large pharmaceutical companies have allocated over $800 billion to R&D. The pharmaceutical services sector has resultingly experienced robust growth and achieved significant scale, which has driven over 30,000 Phase I-III clinical trial starts and nearly 400 novel active substance global launches over the same period.

“Lincoln’s Healthcare Group advises best-in-class platforms operating in highly attractive end markets,” said Emily Wildes, Managing Director & Co-Head of Lincoln’s Healthcare Group. “Pharmaceutical services is a natural fit for our advisory capabilities, particularly as we continue to expand the breadth of solutions we provide to clients.”

Don has advised private equity-backed businesses, private equity sponsors, corporates and owner-operator-led businesses throughout his career. His focus at Lincoln will be advising clients who provide services and technologies to leading life sciences companies across the pharmaceutical services ecosystem, from early-stage discovery, into clinical development, through approval and beyond.

“Early in my career, I worked directly advising leading, innovative biotechnology companies, which has provided me with unique insights into the challenges and pain points throughout drug development stages and how pharmaceutical services companies are best positioned to partner with their clients to address them,” said Don. “I look forward to bringing my unique perspective and transaction experience to Lincoln’s established healthcare advisory platform.”